REG - N4 Pharma PLC - Double siRNA Testing Update

N4 PharmaAnnouncement

04/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221004:nRSD6141Ba&default-theme=true

RNS Number : 6141B  N4 Pharma PLC  04 October 2022

 

4 October 2022

 

N4 Pharma Plc

("N4 Pharma" or the "Company")

Double siRNA Testing Update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec(®), a novel delivery system for cancer treatments and vaccines, is
pleased to announce successful in vitro testing of Nuvec(®) loaded with two
small interfering RNA (siRNA) probes.

 

On 14 September 2022, the Company announced a strategic update highlighting
its intention to focus its further development work on multiple loaded siRNA
on Nuvec(®).

The Company has now completed initial in vitro testing of Nuvec® loaded with
two generic siRNA probes, GFP (Green Fluorescent protein) and EHMT-2
(Euchromatic Histone Lysine Methyltransferase 2) at the same time. The siRNA
probes were loaded onto Nuvec(®) in equal amounts, at a concentration
previously shown to be active. Testing demonstrated that both siRNA probes
when loaded onto Nuvec(®) were able to significantly silence their respective
targets.

 

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"Showing that Nuvec(®) loaded with two generic siRNA probes still achieves
significant silencing of their respective genes is validation for us to now
begin the further work that we announced on 14 September with EGFR and BCl-2
in a PC9 lung cancer model.

 

"Achieving the initial successful testing of Nuvec(®) with the generic GFP
and EHMT-2 siRNA will also allow us to commence commercial outreach
discussions which will only be further strengthened by the results from the
new work we are undertaking."

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 which has been incorporated into UK law by the European
Union (Withdrawal) Act 2018.

 

 

Enquiries:

 

 N4 Pharma Plc                                       Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                      Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)

 IFC Advisory Limited                                Tel: +44 (0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec(®).

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec(®) as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre clinical and
clinical programs, N4 Pharma will seek to receive up front payments, milestone
payments and ultimately royalty payments once products reach the market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMJBATMTJMBTT